Targeting LMW-PTP to sensitize melanoma cancer cells toward chemo- and radiotherapy

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• Tumor resistance to apoptosis is a major challenge in cancer treatment.
• Overexpression of low molecular weight protein tyrosine phosphatase (LMW-PTP) is linked to resistance in cancer cells.
• The specific role of LMW-PTP in melanoma apoptosis resistance requires further investigation.

Purpose of the Study:

• To investigate the role of LMW-PTP in melanoma apoptosis resistance.
• To determine if silencing LMW-PTP enhances sensitivity to dacarbazine, 5-FU, and radiotherapy in melanoma cells.
• To evaluate the efficacy of LMW-PTP inhibition using Morin as an adjuvant therapy.

Main Methods:

• Cell viability assays (MTT, Annexin V/Pi, colony assay) were used to assess drug and radiation sensitivity.
• LMW-PTP was silenced using genetic methods.
• Pharmacological inhibition of LMW-PTP was achieved using Morin.
• Experiments were conducted on A375 melanoma cells and PC3 cells, with in vivo validation.

Main Results:

• Silencing LMW-PTP significantly improved the sensitivity of A375 cells to dacarbazine, 5-FU, and radiotherapy.
• In vivo studies showed that targeting LMW-PTP with Morin enhanced treatment effectiveness.
• Morin synergized with dacarbazine, increasing its cytotoxic activity without affecting non-cancerous cells.
• LMW-PTP knockdown also sensitized PC3 cells to docetaxel and radiotherapy.

Conclusions:

• Targeting LMW-PTP enhances the effectiveness of standard anticancer drugs in melanoma treatment.
• Morin, a LMW-PTP inhibitor, demonstrates potential as an adjuvant therapy to improve outcomes for metastatic melanoma patients.
• Combined treatment with Morin and anticancer drugs shows selectivity, sparing non-cancerous cells.